RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/BC9763268357AF478A873AC5BC0F1B4B0BEE5D5D35ED2F412E92D774D2F59263140B52A021EE7C58BA69DBD3AF2B40F0http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/BC9763268357AF478A873AC5BC0F1B4B0BEE5D5D35ED2F412E92D774D2F59263140B52A021EE7C58BA69DBD3AF2B40F0http://www.w3.org/2000/01/rdf-schema#comment"Data suggest that integrating clinical information with sweat chloride levels cystic fibrosis transmembrane conductance regulator (CFTR) genotype and pancreatic sufficiency provides a context for continued longitudinal monitoring of patients for personalized and effective treatment of cystic fibrosis (CF)."xsd:string
http://purl.uniprot.org/uniprot/#_F59B15F8F16D263650A65AF10A6112DE701994E4EB1C69DB605F548C7878E5C30D2A5C2BA00015758B5601CB3F9E6D4Chttp://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/BC9763268357AF478A873AC5BC0F1B4B0BEE5D5D35ED2F412E92D774D2F59263140B52A021EE7C58BA69DBD3AF2B40F0
http://purl.uniprot.org/uniprot/Q6KEB8http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/BC9763268357AF478A873AC5BC0F1B4B0BEE5D5D35ED2F412E92D774D2F59263140B52A021EE7C58BA69DBD3AF2B40F0
http://purl.uniprot.org/uniprot/#_Q6KEB8-mappedCitation-26671754http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/BC9763268357AF478A873AC5BC0F1B4B0BEE5D5D35ED2F412E92D774D2F59263140B52A021EE7C58BA69DBD3AF2B40F0